Clinical Assessment of Abrocitinib, Tofacitinib, and Cyclosporine in Adult Patients With Moderate to Severe Atopic Dermatitis: A Retrospective Analysis

In our small sample-sized analysis, all treatment groups were found to be efficacious and safe. However, abrocitinib showed a better clinical response than the other two groups in achieving symptom control. However, due to the small sample size, these claims can't be generalized, and further large-scale studies are needed to validate these findings and assess long-term outcomes.